Reports indicate AstraZeneca is in talks with Bristol Myers Squibb about a merger that could be among the largest in pharma history, potentially creating an enlarged company spanning multiple key therapeutic areas. Financial Times coverage says the discussion would combine UK-based AstraZeneca with BMS, though regulatory hurdles remain a central question. A separate report in the feed notes that AstraZeneca shares fell on the speculation tied to merger talks, with attention on potential US regulatory risk under the current administration. In this type of consolidation scenario, review timing, antitrust constraints, and portfolio overlap typically determine whether momentum turns into a signed deal. For industry participants, the main development is that both companies are reportedly exploring a restructuring at a scale that would reshape competition and pipeline strategy across drug categories.